Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis

  1. 1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 36362, Saudi Arabia
  2. 2Research Center, King Fahad Specialist Hospital–Dammam, Eastern Health Cluster, Dammam 32253, Saudi Arabia

Abstract

High immune-cell infiltration does not guarantee effective anti-tumor immunity. Suppression of anti-tumor immunity may explain the variable prognosis and immunotherapy response of immune-inflamed triple-negative breast cancer (TNBC). We asked whether suppression-associated transcriptional signals merely accompanied effector-rich infiltration or retained a distinct association with TNBC across cohorts. Across TCGA-BRCA (discovery, n = 728), METABRIC (replication, n = 1980), and a Saudi exploratory cohort (n = 38), we evaluated a predefined effector immunity composite, an immunoregulatory cell-enrichment composite, and a six-gene suppressive myeloid-associated transcriptional score (CSF3R, OLR1, C5AR1, CLEC4E, ARG2, S100A8). In TCGA-BRCA, the effector immunity composite and six-gene score were both elevated and co-varied strongly (Spearman ρ = 0.66). Notably, the six-gene score remained associated with TNBC after adjustment for effector enrichment and age. The immunoregulatory cell-enrichment composite showed no significant difference, with opposing shifts among its components. In METABRIC, the main findings replicated and all three programs were elevated; the Saudi cohort showed concordant elevation. In a post hoc joint model with all three programs and age, the six-gene score remained positively associated with TNBC in TCGA-BRCA (OR 2.37) and METABRIC (OR 1.27). The six-gene score thus captured reproducible TNBC-associated variation beyond effector enrichment. Our findings motivate investigating whether this myeloid–effector interplay relates to TNBC prognosis and therapy response.

Related

  1. In Silico Single-Cell Transcriptomic Analysis Reveals Senescence-Associated Programs’ Progress Along the Normal–Adenoma–Carcinoma Sequence in Colorectal Cancer
    Xu Zhang, Wangxiong Hu
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  2. Transcriptomic profiling reveals conserved stage‐associated programs across gastrointestinal adenocarcinomas
    Wynston Jay Abenojar, Ron Jacob Avila, Po‐Wei Tsai +1
    Clinical and Translational DiscoveryPeer-reviewedCC BYFull textMolecular biology & gene regulationDOAJ
  3. Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer
    Wei-Chung Shia, Chien-Te Hsieh, Po-Chih Yang +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral biochemistryCrossrefEurope PMC
  4. Single-cell and bulk transcriptomic analysis of inflammation-metabolism programs and the tumor microenvironment of colorectal cancer liver metastasis
    Zhen Ma, Wen Jiang, Jian Zhang +4
    Translational OncologyPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
  5. Co-Enrichment of Desulfovibrio and Erysipelotrichaceae and Dysregulation of Multiple Amino Acid Pathways in HFpEF: Insights into TXG-Associated Metabolic Changes
    Wei Zhang, Yiyi Zhu, Xiaosu Chu +3
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
BibTeX
@article{omair2026suppressionassociated,
  title = {{Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis}},
  author = {Shorog Al Omair and Fahad Almsned},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210208},
  url = {https://www.mdpi.com/1422-0067/27/22/10208},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Suppression-Associated Immune Programs in Triple-Negative Breast Cancer Beyond Effector Enrichment: A Multi-Cohort Transcriptomic Analysis
AU  - Shorog Al Omair
AU  - Fahad Almsned
PY  - 2026
DA  - 2026/11/14
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210208
UR  - https://www.mdpi.com/1422-0067/27/22/10208
AB  - High immune-cell infiltration does not guarantee effective anti-tumor immunity. Suppression of anti-tumor immunity may explain the variable prognosis and immunotherapy response of immune-inflamed triple-negative breast cancer (TNBC). We asked whether suppression-associated transcriptional signals merely accompanied effector-rich infiltration or retained a distinct association with TNBC across cohorts. Across TCGA-BRCA (discovery, n = 728), METABRIC (replication, n = 1980), and a Saudi exploratory cohort (n = 38), we evaluated a predefined effector immunity composite, an immunoregulatory cell-enrichment composite, and a six-gene suppressive myeloid-associated transcriptional score (CSF3R, OLR1, C5AR1, CLEC4E, ARG2, S100A8). In TCGA-BRCA, the effector immunity composite and six-gene score were both elevated and co-varied strongly (Spearman ρ = 0.66). Notably, the six-gene score remained associated with TNBC after adjustment for effector enrichment and age. The immunoregulatory cell-enrichment composite showed no significant difference, with opposing shifts among its components. In METABRIC, the main findings replicated and all three programs were elevated; the Saudi cohort showed concordant elevation. In a post hoc joint model with all three programs and age, the six-gene score remained positively associated with TNBC in TCGA-BRCA (OR 2.37) and METABRIC (OR 1.27). The six-gene score thus captured reproducible TNBC-associated variation beyond effector enrichment. Our findings motivate investigating whether this myeloid–effector interplay relates to TNBC prognosis and therapy response.
SN  - 1422-0067
ER  -